Skip to main content
. 2014 Oct;6(10):a016295. doi: 10.1101/cshperspect.a016295

Figure 4.

Figure 4.

IL-6 receptor system and IL-6 blocker, a humanized anti-IL-6 receptor antibody tocilizumab. IL-6 binds to soluble and transmembrane IL-6R and the complex, then induces homodimerization of gp130, leading to activation of the signaling system. A humanized anti-IL-6R antibody, tocilizumab, blocks IL-6-mediated signaling pathway by its inhibition of IL-6 binding to both receptors. JAKs, Janus kinases; SHP-2, SH2-domain containing protein tyrosine phosphatase-2.